IL17A and hepatocellular carcinoma: Based on recent pilot studies showing the correlation of high IL-17 levels with various liver-related clinical endpoints [28, 30, 33, 35, 37, 44, 45], we performed a prospective cohort study, which showed that the circulatory IL-17 concentration can serve as a clinical biomarker for predicting imminent HCC.